{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:31:49Z","timestamp":1783074709849,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP170719"],"award-info":[{"award-number":["RP170719"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK56338"],"award-info":[{"award-number":["DK56338"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA249867"],"award-info":[{"award-number":["R01 CA249867"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RP170074"],"award-info":[{"award-number":["RP170074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA125123"],"award-info":[{"award-number":["CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RR024574"],"award-info":[{"award-number":["RR024574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001287","name":"Elsa U Pardee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.exphem.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T21:50:02Z","timestamp":1647467402000},"page":"34-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-7739","authenticated-orcid":false,"given":"Jacob J.","family":"Junco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Zorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3416-230X","authenticated-orcid":false,"suffix":"Jr.","given":"Vincent U.","family":"Gant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Daniel","family":"Lacorazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Sumazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.03.005_bib0001","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.005_bib0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down's syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2022.03.005_bib0003","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2022.03.005_bib0004","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.005_bib0005","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2022.03.005_bib0006","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","article-title":"Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia","volume":"144","author":"Gaikwad","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.03.005_bib0007","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.005_bib0008","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.005_bib0009","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2014-03-560847","article-title":"Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003","volume":"124","author":"O'Connor","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.005_bib0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/bjh.12739","article-title":"Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol","volume":"165","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.03.005_bib0011","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/hmg\/ddm086","article-title":"Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities","volume":"16","author":"Li","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.exphem.2022.03.005_bib0012","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1073\/pnas.1211405109","article-title":"Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21","volume":"109","author":"Roy","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2022.03.005_bib0013","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ng.2949","article-title":"Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation","volume":"46","author":"Lane","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2022.03.005_bib0014","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1089\/ars.2010.3798","article-title":"Defective hematopoietic stem cell and lymphoid progenitor development in the Ts65Dn mouse model of Down syndrome: potential role of oxidative stress","volume":"15","author":"Lorenzo","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.exphem.2022.03.005_bib0015","first-page":"1","article-title":"Characterization of B lymphopoiesis in mouse bone marrow and spleen","volume":"271","author":"Hardy","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2022.03.005_bib0016","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1182\/blood-2008-01-129049","article-title":"IRF8 regulates B-cell lineage specification, commitment, and differentiation","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.005_bib0017","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.1073\/pnas.96.17.9797","article-title":"Functional characterization of B lymphocytes generated in vitro from embryonic stem cells","volume":"96","author":"Cho","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2022.03.005_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.exphem.2022.03.005_bib0019","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2011.128","article-title":"Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles","volume":"25","author":"Loudin","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.005_bib0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-018-0641-1","article-title":"Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia","volume":"11","author":"Ghelli Luserna Di Rora","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2022.03.005_bib0021","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.005_bib0022","doi-asserted-by":"crossref","first-page":"E4030","DOI":"10.1073\/pnas.1702489114","article-title":"Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome","volume":"114","author":"Schwartzman","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.exphem.2022.03.005_bib0023","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2013.085175","article-title":"Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features","volume":"98","author":"Schwab","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2022.03.005_bib0024","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2022.03.005_bib0025","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1158\/0008-5472.CAN-08-0121","article-title":"A small-molecule E2F inhibitor blocks growth in a melanoma culture model","volume":"68","author":"Ma","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.005_bib0026","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","article-title":"Combined Inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2022.03.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.068","article-title":"Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1","volume":"31","author":"Romero-Pozuelo","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2022.03.005_bib0028","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41598-017-01729-w","article-title":"Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2022.03.005_bib0029","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/leu.2014.350","article-title":"Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA","volume":"29","author":"Chae","year":"2015","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22001278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22001278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:12:35Z","timestamp":1777547555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22001278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"alternative-id":["S0301472X22001278"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.03.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}